Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: Results of a phase i study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 273-280

  Gross, Mitchell E ^a   Leichman, Lawrence ^b   Lowe, Elizabeth S ^c   Swaisland, Alan ^c,d   Agus, David B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DESERT REGIONAL MEDICAL CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d TheraKin Consulting Ltd   (United Kingdom)

Author keywords

Epidermal growth factor receptor; gefitinib; Pharmacokinetics; Solid tumors; Tyrosine kinase inhibitor

Indexed keywords

GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPERURICEMIA; HYPOGLYCEMIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84856722365     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1757-y     Document Type: Article

References (22)

1. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa J-Y Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova R-P Dong J Baselga 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237 2246 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
2. ES Kim V Hirsch T Mok MA Socinski R Gervais Y-L Wu L-Y Li CL Watkins MV Sellers ES Lowe Y Sun M-L Liao K Østerlind M Reck AA Armour FA Shepherd SM Lippman J-Y Douillard 2008 Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 1809 1818 19027483 10.1016/S0140-6736(08)61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM
3. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial JAMA 290 2149 2158 14570950 10.1001/jama.290.16.2149 1:CAS:528:DC%2BD3sXosVOnsbo%3D (Pubitemid 37432975)
4. N Thatcher A Chang P Parikh PJ Rodrigues T Ciuleanu J von Pawel S Thongprasert EH Tan K Pemberton V Archer K Carroll 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer) Lancet 366 1527 1537 16257339 10.1016/S0140-6736(05)67625-8 1:CAS:528:DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
5. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan DC Sgroi B Muir MJ Riemenschneider RB Iacona AD Krebs DH Johnson G Giaccone RS Herbst C Manegold M Fukuoka MG Kris J Baselaga JS Ochs DA Haber 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 8081 8092 16204011 10.1200/JCO.2005.02.7078 1:CAS:528:DC%2BD2MXht1CqsLzM (Pubitemid 46657411)
6. J-Y Douillard FA Shepherd V Hirsh T Mok MA Socinski R Gervais ML Liao H Bischoff M Reck MV Sellers CL Watkins G Speake AA Armour ES Kim 2010 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 744 752 20038723 10.1200/JCO.2009.24.3030 1:CAS:528: DC%2BC3cXksVyrsbY%3D
7. FR Hirsch M Varella-Garcia PA Bunn Jr WA Franklin R Dziadziuszko N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu J von Pawel C Watkins A Flannery G Ellison E Donald L Knight D Parums N Botwood B Holloway 2006 Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 5034 5042 17075123 10.1200/JCO.2006.06.3958 1:CAS:528:DC%2BD28Xht1GnurzF (Pubitemid 46631407)
8. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
9. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WR Sellers BE Johnson M Meyerson 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
10. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria B Singh R Heelan V Rusch L Fulton E Mardis D Kupfer R Wilson M Kris H Varmus 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306 13311 15329413 10.1073/pnas.0405220101 1:CAS:528: DC%2BD2cXnvFems70%3D (Pubitemid 39209661)
11. TS Mok Y-L Wu S Thongprasert C-H Yang D-T Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose Y Nishiwaki Y Ohe J-J Yang B Chewaskulyong H Jiang EL Duffield CL Watkins AA Armour M Fukuoka 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
12. M Maemondo A Inoue K Kobayashi S Sugawara S Oizumi H Isobe A Gemma M Harada H Yoshizawa I Kinoshita Y Fujita S Okinaga H Hirano K Yoshimori T Harada T Ogura M Ando H Miyazawa T Tanaka Y Saijo K Hagiwara S Morita T Nukiwa The North-East Japan Study Group 2010 Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380 2388 20573926 10.1056/NEJMoa0909530 1:CAS:528:DC%2BC3cXot1Gjt7Y%3D
13. T Mitsudomi S Morita Y Yatabe S Negoro I Okamoto J Tsurutani T Seto M Satouchi H Tada T Hirashima K Asami N Katakami M Takada H Yoshioka K Shibata S Kudoh E Shimizu H Saito S Toyooka K Nakagawa M Fukuoka The West Japan Oncology Group 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121 128 20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
14. J Anido P Matar J Albanell M Guzmán F Rojo J Arribas S Averbuch J Baselga 2003 ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin Cancer Res 9 1274 1283 12684395 1:CAS:528:DC%2BD3sXislertrs%3D (Pubitemid 36418377)
15. ML Janmaat FAE Kruyt JA Rodriguez G Giaccone 2003 Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 2316 2326 12796401 1:CAS:528:DC%2BD3sXksVajs78%3D (Pubitemid 36687658)
16. J Albanell F Rojo S Averbuch A Feyereislova JM Mascaro R Herbst P LoRusso D Rischin S Sauleda J Gee RI Nicholson J Baselga 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 110 124 11773160 10.1200/JCO.20.1.110 1:CAS:528: DC%2BD38XnsFersQ%3D%3D (Pubitemid 34032602)
17. MM Moasser A Basso SD Averbuch N Rosen 2001 The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 61 7184 7188 11585753 1:CAS:528:DC%2BD3MXnsVehtrY%3D (Pubitemid 32946513)
18. M Ono M Kuwano 2006 Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 7242 7251 17189395 10.1158/1078-0432.CCR-06-0646 1:CAS:528:DC%2BD28XhtlCrtr7M (Pubitemid 46095395)
19. HK Jones LE Stafford HC Swaisland R Payne 2002 A sensitive assay for ZD1839 ('Iressa') in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in phase I clinical trials J Pharm Biomed Anal 29 221 228 12062681 10.1016/S0731-7085(02)00014-6 1:CAS:528:DC%2BD38Xktlynu7c%3D (Pubitemid 34621284)
20. M Ranson LA Hammond D Ferry M Kris A Tullo PI Murray V Miller S Averbuch J Ochs C Morris A Feyereislova H Swaisland EK Rowinsky 2002 ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2240 2250 11980995 10.1200/JCO.2002.10.112 1:CAS:528:DC%2BD38XktVKrsrc%3D (Pubitemid 34441651)
21. Y Rukazenkov G Speake G Marshall J Anderton BR Davies RW Wilkinson DM Hickinson A Swaisland 2009 Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs 20 856 866 19657272 10.1097/CAD.0b013e32833034e1 1:CAS:528:DC%2BD1MXht1GitrvN
22. MG Fury DB Solit YB Su N Rosen FM Sirotnak RP Smith CG Azzoli JE Gomez VA Miller MG Kris BA Pizzo R Henry DG Pfister NA Rizvi 2007 A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors Cancer Chemother Pharmacol 59 467 475 16896930 10.1007/s00280-006-0286-6 1:CAS:528:DC%2BD2sXlslaisA%3D%3D (Pubitemid 46122325)